Core--cell, tissue and animal facility

描述：（由申请人提供）：此核心的目的是帮助 设计针对治疗和/或 预防人类免疫缺陷病毒引起的神经系统疾病 1型（HIV-1）感染。在这方面，纯化的人单核细胞衍生的 巨噬细胞（MDM）和MDM条件培养基（MCM）， HIV-1感染和/或免疫激活，应要求提供给所有研究者， 在罗切斯特合作神经艾滋病药物发现组（RCNDDG）。在 此外，开发了有前途的抗炎和/或神经保护药物， 在实验室试验或拟定的试验中， HIV-1脑炎的严重联合免疫缺陷（SCID）小鼠模型 （蜂巢）。将提供脑组织和/或血清用于测量药物 HIVE小鼠中的水平和病理。这些作品将支持翻译 （工作台到床边）的研究工作，并直接影响性能 随后的临床试验。这些作品，总的来说，是基于这样一个概念， HIV-1相关性痴呆（HAD）部分是一种可逆的代谢性疾病， 病毒感染单核细胞免疫缺陷性脑病 吞噬细胞[（MP）、小胶质细胞、血管周围和实质巨噬细胞]。这些 MP既作为生产性HIV-1感染的储存库， 中枢神经系统（CNS）内神经毒性活动的来源。的 开发抑制脑中毒性炎症活动的方法可能 有助于改善和预防持续性病毒感染的并发症 脑内复制作为关键的后续治疗， 有效的抗逆转录病毒疗法，这是RCNDDG的主要目标。

DESCRIPTION: (Provided by applicant): The purpose of this core is to assist in the design of adjunctive therapeutic strategies for treatment and/or prevention of neurologic disease following human immunodeficiency virus type-one (HIV-1) infection. In this regard, purified human monocyte-derived macrophages (MDM) and MDM conditioned media (MCM) will be supplied, following HIV-1 infection and/or immune activation, to all investigators on request, within the Rochester Cooperative NeuroAIDS Drug Discovery Group (RCNDDG). In addition, promising anti-inflammatory and/or neuroprotective drugs, developed in laboratory assays or proposed, will be tested for therapeutic efficacy in a severe combined immune deficiency (SCID) mouse model of HIV-1 encephalitis (HIVE). Brain tissue and/or sera will be made available for measuring drug levels and pathology in the HIVE mice. Such works will support translational (bench to bedside) research efforts and directly effect the performance of subsequent clinical trials. The works, in toto, are based on the concept that HIV-1 associated dementia (HAD) is, in part, a reversible metabolic encephalopathy caused by defective immunity of virus-infected mononuclear phagocytes [(MP), microglia, perivascular and parenchymal macrophages]. These MPs serve both as reservoirs for productive HIV-1 infection and principal sources of neurotoxic activities within the central nervous system (CNS). The development of ways to inhibit toxic inflammatory activities in brain may serve to both ameliorate and prevent complications of persistent viral replication in brain serving as critical adjunctive therapies to ongoing potent anti-retroviral regimens, the principal goals of the RCNDDG.